GLP-1 Weight Loss Calculator

Estimate your potential weight loss on Wegovy or Mounjaro based on clinical trial outcomes and your starting weight.

What clinical trials show

Wegovy (semaglutide 2.4mg): average 15–17% body weight loss at 68 weeks in the STEP trials. Mounjaro (tirzepatide 15mg): average 20–22.5% body weight loss at 72 weeks in the SURMOUNT trials.

Individual results vary

These are averages from controlled trials. Real-world results depend on adherence, starting weight, diet, exercise, and individual metabolic response.